SCHEMBL2392851

SCHEMBL2392851

O=C(O)CCc1ccc(Cl)cc1O

nearest known ligand 0.68

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.58
FFAR1 O14842 4/20 0.50
FFAR4 Q5NUL3 3/20 0.50
NPSR1 Q6W5P4 1/20 0.46
HDAC6 Q9UBN7 1/20 0.45
ALOX15 P16050 1/20 0.44
MAPK1 P28482 1/20 0.44
GPR17 Q13304 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
PDPK1 O15530 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31155820 1.00 POLB (0.58) POLBFFAR1FFAR4NPSR1HDAC6
SCHEMBL18780574 0.88 F13A1 (0.51) POLB
SCHEMBL1418003 0.87 HIF1A (0.59) POLBFFAR1FFAR4NPSR1HDAC6
SCHEMBL28052429 0.87 CYP3A4 (0.44) POLBALOX15CA1CA2PDPK1
SCHEMBL8359383 0.84 FFAR1 (0.64) POLBFFAR1FFAR4
SCHEMBL30567601 0.83 PDPK1 (0.59) FFAR1GPR17PDPK1
SCHEMBL586345 0.83 PDPK1 (0.59) FFAR1GPR17PDPK1
SCHEMBL2394432 0.82 KEAP1 (0.53) POLBALOX15CA1CA2
SCHEMBL20253199 0.82 POLB (0.50) POLBFFAR1FFAR4NPSR1GPR17
SCHEMBL14430375 0.81 FFAR1 (0.54) POLBFFAR1FFAR4NPSR1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102557971-B Substituted acids for the treatment of respiratory diseases ASTRAZENECA AB 2015-06-17 CN disclosed
EP-1765768-B1 SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES ASTRAZENECA AB (SE) 2013-11-06 EP disclosed
CN-102557971-A Substituted acids for the treatment of respiratory diseases ASTRAZENECA AB 2012-07-11 CN disclosed
CN-101014564-B Substituted acids for the treatment of respiratory diseases ASTRAZENECA AB 2012-05-09 CN disclosed
US-8022248-B2 3-[2-(3-Cyanophenoxy)-4-(trifluoromethyl)phenyl]propanoic acid;prostaglandin D2 inhibitor, orphan receptor CRTH2 antagonist; antiinflammatory, analgesic, antipyretic; respiratory system disorders: asthma and rhinitis; coupling amino/thio-phenyl derivatives with ester followed by hydrolysis to acid ASTRAZENECA AB (SE) 2011-09-20 US disclosed
US-20080114002-A1 Substituted Acids for the Treatment of Respiratory Diseases ASTRAZENECA AB (SE) 2008-05-15 US disclosed
CN-101014564-A Substituted acids for the treatment of respiratory diseases ASTRAZENECA AB (SE) 2007-08-08 CN disclosed
EP-1765768-A1 SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES AstraZeneca AB (SE) 2007-03-28 EP disclosed
WO-2006005909-A1 SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES ASTRAZENECA AB (SE) 2006-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114002-A1 Substituted Acids for the Treatment of Respiratory Diseases HRH2, HRH1, HRH4 POLB 2888/4885FFAR1 23/4885FFAR4 133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.